June 26, 2017

Anti-obesity start-up Antag Therapeutics ApS raises 2.7 mEUR with Novo Seeds

Antag Therapeutics ApS is founded on decades of seminal research focused on peptide-based drugs and dietary-related metabolic diseases from Professors Mette M. Rosenkilde and Jens J. Holst at the University of Copenhagen. In collaboration with clinicians from Gentofte and Bispebjerg hospital, the team has discovered a naturally occurring peptide-antagonist of the Glucose-dependent Insulinotropic Polypeptide (GIP) receptor and has conducted several human studies with demonstrated effects on fat metabolism.